<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01729156</url>
  </required_header>
  <id_info>
    <org_study_id>C11palmitatMetformin</org_study_id>
    <nct_id>NCT01729156</nct_id>
  </id_info>
  <brief_title>Effects of Metformin on Hepatic FFA Metabolism</brief_title>
  <official_title>Effects of Metformin on Hepatic Free Fatty Acid Metabolism in Patients Diagnosed With Type 2 Diabetes: A C11 PET Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lars Christian Gormsen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Metformin treatment has beneficial effects on both glucose and lipid metabolism.
      Whereas there is general agreement that the blood glucose lowering effect of metformin
      results from inhibition of hepatic gluconeogenesis, it is less clear exactly how the drug
      lowers blood triglyceride concentration. There are indications that it enhances hepatic free
      fatty acid (FFA) oxidation thus diminishing substrate for reesterification and resecretion as
      very-low-density-lipoprotein (VLDL) triglycerides (TG). However, the liver is not easily
      accessible for sampling in humans and data on the clinical effects of metformin in the liver
      are therefore lacking. This may change due to the increasing use of the positron emission
      tomography (PET) technique. Using PET isotopes (11C or 18F) coupled to either palmitate or a
      fatty acid analogue, it is possible to non-invasively measure hepatic fatty acid handling.

      Aim: To determine how 3 months metformin treatment (1000 mg twice daily) affects hepatic
      lipid metabolism in patients with newly diagnosed type 2 diabetes.

      Design: Randomized, placebo controlled, double-blind parallel study with patients receiving
      either metformin or placebo. A control group of BMI and age-matched healthy controls will
      receive metformin for 3 months.

      Hypothesis: Metformin lowers VLDL-TG secretion and circulating triglycerides by increasing
      hepatic fatty acid oxidation
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">May 5, 2017</completion_date>
  <primary_completion_date type="Actual">May 5, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatic fatty acid oxidation</measure>
    <time_frame>06/01/2015</time_frame>
    <description>Hepatic fatty acid oxidation assessed by dynamic C11-palmitate PET</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hepatic fatty acid reesterification</measure>
    <time_frame>06/01/2015</time_frame>
    <description>Hepatic fatty acid reesterification assessed by C11-palmitate PET</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hepatic fatty acid uptake</measure>
    <time_frame>06/01/2015</time_frame>
    <description>Hepatic fatty acid uptake assessed by C11-palmitate PET</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VLDL-TG secretion</measure>
    <time_frame>06/01/2015</time_frame>
    <description>Hepatic VLDL-TG secretion assessed by [1-14C] VLDL tracer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight loss</measure>
    <time_frame>06/01/2015</time_frame>
    <description>Weight loss after metformin treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatty acid turnover</measure>
    <time_frame>06/01/2015</time_frame>
    <description>Fatty acid turnover assessed as whole body C11-palmitate turnover</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VLDL-TG oxidation</measure>
    <time_frame>06/01/2015</time_frame>
    <description>VLDL-TG oxidation assessed by 14C carbon dioxide (CO2) in exhaled breath</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy controls receiving 1000 mg metformin twice daily for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin &quot;Sandoz&quot;, 1000 mg twice daily for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>1000 mg metformin twice daily in 3 months</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Metformin &quot;Sandoz&quot; 500 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 tablets twice daily in 3 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed type 2 diabetes (&gt;3 and &lt;12 months)

          -  Age 50-70 years

          -  BMI&lt;40

        Exclusion Criteria:

          -  Metformin treatment &gt;6 months

          -  NASH (non alcoholic steatohepatitis)

          -  Cancer

          -  Anemia

          -  HbA1C&gt;8.5 %

          -  Chronic or acute pancreatitis

          -  Alcohol or medicine abuse

          -  Allergy towards metformin

          -  Claustrophobia

          -  Severe obesity (weight &gt;130 kilogram)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars C Gormsen, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2012</study_first_submitted>
  <study_first_submitted_qc>November 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2012</study_first_posted>
  <last_update_submitted>May 4, 2017</last_update_submitted>
  <last_update_submitted_qc>May 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Lars Christian Gormsen</investigator_full_name>
    <investigator_title>Senior Registrar, MD PhD</investigator_title>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Hepatic fatty acid oxidation</keyword>
  <keyword>Dyslipidemia</keyword>
  <keyword>Metformin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

